What the trial found
The CONNECT randomized trial, published in the New England Journal of Medicine on October 14, assigned 283 adults with type 2 diabetes who were not using insulin to continuous glucose monitoring or routine care. Conducted at 22 U.S. primary care practices over 26 weeks, it found a greater reduction in glycated hemoglobin with monitoring. The adjusted between-group difference was 0.9 percentage points in favor of monitoring, with a 95% confidence interval of 0.6 to 1.1 points.
What was measured
Average A1c fell from 8.8% to 7.2% in the monitoring group and from 8.7% to 8.0% with routine care. Time within the study's glucose range of 70–180 mg/dL was 21 percentage points higher with monitoring. No severe hypoglycemia events were reported. Dexcom funded the trial; Reuters' October 16 coverage identifies the device as the Dexcom G7 and independently reports the main A1c results.
Analysis: stronger evidence, narrower conclusions
Random assignment makes this more informative than comparing people who independently choose to buy a sensor with those who do not. The result supports a benefit under the trial's conditions. It does not establish that every person with diabetes needs the device, that sensors replace clinical care or that six-month improvements necessarily prevent later complications. A glucose-control endpoint and a long-term health outcome answer different questions; readers should not silently substitute one for the other.
What to watch next
The study was presented in part at the American Diabetes Association meeting in June; the fresh development is the October journal publication and subsequent reporting, not a claim that the findings first appeared this week. Longer follow-up, affordability and practical use outside a trial remain important questions. This article is a report on evidence, not advice to change medication or monitoring without a treating clinician.
What remains unresolved
The 26-week results do not establish persistence or fewer long-term complications.
Affordability and routine-care implementation require further evidence.
Development timeline
Initial synthesis of the October 14 peer-reviewed CONNECT report and October 16 coverage, distinguishing glycemic endpoints from unproven long-term outcomes and noting earlier conference presentation.
The source trail
These sources support this report. Multiple documents from one organization are not independent corroboration.
